---
title: "Why Is Virax Biolabs (VRAX) Stock Trending Overnight?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286858214.md"
description: "Virax Biolabs (VRAX) shares surged 17.36% to $0.28 in after-hours trading, following a 53.09% intraday gain. Armistice Capital disclosed a 4.99% stake in VRAX. The company is advancing ViraxImmune, targeting post-acute infection syndromes. Despite a market cap of $4.79 million, VRAX's stock has dropped 78.04% over the past year, trading closer to its 52-week low of $0.10."
datetime: "2026-05-19T05:09:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286858214.md)
  - [en](https://longbridge.com/en/news/286858214.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286858214.md)
---

# Why Is Virax Biolabs (VRAX) Stock Trending Overnight?

**Virax Biolabs Group Limited ( VRAX )** shares are trending on Tuesday.

VRAX shares rose 17.36% to $0.28 in after-hours trading on Monday.

The jump in the late trading session follows an intraday gain of 53.09%, closing the stock at $0.24, according to Benzinga Pro data.

## Armistice Capital Takes 4.99% Stake in VRAX

On May 15, **Armistice Capital**, LLC, a New York-based hedge fund, filed a **Securities and Exchange Commission** disclosure revealing a 4.99% beneficial ownership stake of over 1 million ordinary shares. The fund was founded in 2012 by Managing Member **Steven Boyd**, who signed the filing.

Last month, Virax Biolabs ( VRAX ) announced it is advancing **ViraxImmune**, a proprietary assay targeting post-acute infection syndromes including Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a space the company estimates carries a U.S. economic burden exceeding $25 billion.

## Trading Metrics, Technical Analysis

Virax, an innovative biotechnology company, has a market capitalization of $4.79 million. Its stock has traded between a 52-week high of $1.18 and a 52-week low of $0.10.

VRAX's Relative Strength Index (RSI) is 69.52.

Over the past 12 months, the stock of the biotech has dropped 78.04%.

Currently, VRAX is positioned at about 13% of the way up from its 52-week low to its high, meaning the stock is trading closer to its annual low.

**Benzinga’s Edge Stock Rankings** indicate that VRAX has a negative price trend across all time frames.

<figure class="wp-block-image aligncenter size-full is-resized"\></figure\>

_Photo Courtesy: Gorodenkoff on Shutterstock.com_

**Disclaimer:** This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

**Read Also: Bakkt (BKKT) Stock Jumps Over 16% After Hours: Here's Why The ICE-Backed Crypto Platform Is Trending Overnight**

### Related Stocks

- [VRAX.US](https://longbridge.com/en/quote/VRAX.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BKKT.US](https://longbridge.com/en/quote/BKKT.US.md)
- [BKKT+.US](https://longbridge.com/en/quote/BKKT+.US.md)

## Related News & Research

- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results](https://longbridge.com/en/news/286319406.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Virax Mulls Bringing UK Biotech Startup’s Immune Profiling Platform to China, Chair Says](https://longbridge.com/en/news/285902519.md)
- [Precigen Q1 revenue beats estimates on PAPZIMEOS launch](https://longbridge.com/en/news/286311056.md)